Chimeric molecule, pharmaceutical composition, method for cleaving target nucleic acid, and kit for cleaving target nucleic acid or for diagnosis

The chimeric molecule addresses off-target effects and low-dose efficacy issues in nucleic acid drugs by using a dual-nucleic acid structure with ribonuclease H for catalytic cleavage, ensuring efficient target nucleic acid inhibition and rapid turnover.

JP7577337B2Active Publication Date: 2024-11-05TOHOKU UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2021534069
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-07-24
Filing Date
2020-07-22
Publication Date
2024-11-05
Estimated Expiration
2040-07-22

AI Technical Summary

Technical Problem

Nucleic acid drugs face challenges with off-target effects and reduced efficacy at low doses due to insufficient turnover rates and complex stability, limiting their therapeutic potential.

Method used

A chimeric molecule design that includes a first nucleic acid derivative with a neutral or cationic main chain skeleton fused to a second nucleic acid with an anionic main chain skeleton, specifically binding to target nucleic acids and utilizing ribonuclease H for catalytic cleavage, allowing rapid dissociation post-cleavage to enhance turnover efficiency.

Benefits of technology

The chimeric molecule effectively inhibits target nucleic acid function at low concentrations while minimizing off-target effects by promoting rapid dissociation and increasing turnover rates, enhancing therapeutic efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007577337000014
    Figure 0007577337000014
  • Figure 0007577337000015
    Figure 0007577337000015
  • Figure 0007577337000016
    Figure 0007577337000016
Patent Text Reader

Abstract

Provided are: a chimeric molecule in which are fused a first nucleic acid or a derivative thereof that has the ability to bind to a target nucleic acid, and a second nucleic acid or a derivative thereof that has the ability to bind to the target nucleic acid, the main chain skeleton of the second nucleic acid or the derivative thereof being anionic; a pharmaceutical composition including the chimeric molecule; a method for cleaving a target nucleic acid using the chimeric molecule; and a kit for target nucleic acid cleavage or diagnosis that includes the chimeric molecule.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a chimeric molecule, a pharmaceutical composition, a method for cleaving a target nucleic acid, and a kit for cleaving a target nucleic acid or for diagnosis. This application claims priority based on Japanese Patent Application No. 2019-136414, filed on July 24, 2019, the contents of which are incorporated herein by reference. [Background technology]

[0002] In recent years, nucleic acid drugs have been attracting attention as next-generation molecular targeted drugs, similar to antibody drugs. In particular, nucleic acid drugs can be used to treat diseases that cannot be treated with antibody drugs. In addition, they have many advantages, such as being relatively inexpensive to supply through chemical synthesis, and, like antibody drugs, they are establishing their position as post-small molecule drugs.

[0003] Numerous drug strategies have been reported for nucleic acid drugs. For example, antisense nucleic acids (ASOs) target messenger RNA (mRNA), microRNA (miRNA), and siRNA (siRNA) involved in disease progression, selectively recognize the target with a base sequence, and suppress the function of the target RNA by forming a complex, thereby exerting a therapeutic effect. In order for these nucleic acid drugs to effectively exert their pharmacological effects, 1) high in vivo stability and 2) high specificity for the target nucleic acid and complex stability are required, and the development of modified oligonucleotides / artificial oligonucleotides that have been chemically modified from natural DNA / RNA is being actively researched.

[0004] Although excellent modified or artificial nucleic acids have been reported to date, side effects resulting from binding to non-target nucleic acids with similar sequences to the target nucleic acid (off-target effects in the narrow sense) and toxicity specific to nucleic acid drugs that does not depend on target nucleic acid recognition (off-target effects in the broad sense) have been identified as issues that must be resolved for practical application, and research is being conducted worldwide to reduce and improve these issues.

[0005] Reducing the dosage of nucleic acid drugs has been proposed as a methodology for overcoming off-target effects in a broad sense. However, reducing the dosage naturally leads to a decrease in the amount of complex formed with the target RNA, and effective drug efficacy cannot be expected. Specifically, feedback mechanisms have been reported not only in systems targeting mRNAs with sub-μM expression levels using ASOs, which have been reported to have a limit of sub-nM levels of intracellular introduction, but also in systems targeting miRNAs that function at nM-pM levels of intracellular expression, and it has been pointed out that a drug efficacy strategy based on 1:1 complex formation between target RNA and ASO cannot be expected to have sufficient therapeutic effects. As a solution to this problem, nucleic acid drugs with catalytic functions that utilize RNase H, which catalytically cleaves target RNA with a small amount of ASO, have attracted attention (Non-Patent Document 1). [Prior art documents] [Non-patent literature]

[0006] [Non-Patent Document 1] Liang, X. et al., Mol. Ther. 2017, 25, 2075 Summary of the Invention [Problem to be solved by the invention]

[0007] The present invention aims to provide a chimeric molecule that can inhibit the function of a target nucleic acid at a low concentration and suppress off-target effects, a pharmaceutical composition containing the chimeric molecule, a method for cleaving a target nucleic acid using the chimeric molecule, and a kit for cleaving or diagnosing a target nucleic acid that contains the chimeric molecule. [Means for solving the problem]

[0008] The present inventors considered that increasing the metabolic turnover number is effective in improving the efficiency of cleavage of target RNA by RNase. From this perspective, by focusing on the dissociation process after RNA cleavage, they proposed a design method that contributes to the construction of an oligonucleic acid system that can be rapidly dissociated from the target RNA complex after cleavage, and successfully demonstrated it. They found that by using this method, the function of the target nucleic acid can be suppressed at a low concentration and off-target effects can be suppressed, and thus completed the present invention. The present invention includes the following aspects. [1] A chimeric molecule comprising a first nucleic acid or a derivative thereof capable of binding to a target nucleic acid fused with a second nucleic acid or a derivative thereof capable of binding to the target nucleic acid and having an anionic main chain backbone. [2] The chimeric molecule described in [1], wherein the main chain backbone of the first nucleic acid or its derivative is neutral or cationic. [3] The chimeric molecule according to [2], wherein the main chain backbone of the first nucleic acid or its derivative is an amide backbone. [4] The chimeric molecule according to any one of [1] to [3], wherein the main chain backbone of the second nucleic acid or a derivative thereof is a sugar-phosphate backbone. [5] The chimeric molecule according to any one of [1] to [4], wherein the first nucleic acid or a derivative thereof is fused to the 5' end of the second nucleic acid or a derivative thereof. [6] The chimeric molecule according to any one of [1] to [4], wherein the first nucleic acid or a derivative thereof is fused to the 3' end of the second nucleic acid or a derivative thereof. [7] The chimeric molecule described in any one of [1] to [6], wherein a complex consisting of the chimeric molecule and the target nucleic acid bound to the chimeric molecule specifically binds to a nuclease. [8] The chimeric molecule described in [7], wherein the nuclease cleaves the target nucleic acid at the fusion portion between the first nucleic acid or a derivative thereof and the second nucleic acid or a derivative thereof. [9] The chimeric molecule described in [8], wherein the melting temperature Tm of both fragments of the target nucleic acid after cleavage with the nuclease is 38°C or lower.

[10] The chimeric molecule according to any one of [7] to [9], wherein the nuclease is ribonuclease H.

[11] The chimeric molecule according to any one of [1] to

[10] , wherein the first nucleic acid or a derivative thereof is a peptide nucleic acid or a peptide ribonucleic acid or a derivative thereof.

[12] The chimeric molecule according to any one of [1] to

[11] , wherein the second nucleic acid or a derivative thereof is DNA.

[13] The chimeric molecule according to any one of [1] to

[12] , wherein the target nucleic acid is RNA or DNA.

[14] A pharmaceutical composition comprising, as an active ingredient, the chimeric molecule according to any one of [1] to

[13] .

[15] The pharmaceutical composition described in

[14] , wherein the pharmaceutical composition is for treating cancer or an ischemic brain disease.

[16] A method for cleaving a target nucleic acid, comprising cleaving the target nucleic acid using the chimeric molecule according to any one of [1] to

[13] and a nuclease.

[17] The method for cleaving a target nucleic acid according to

[16] , wherein the nuclease is ribonuclease H.

[18] A kit for cleaving a target nucleic acid or for diagnosis, comprising the chimeric molecule according to any one of [1] to

[13] and a nuclease.

[19] The kit described in

[18] , wherein the nuclease is ribonuclease H. Effect of the Invention

[0009] According to the present invention, there are provided a chimeric molecule that can inhibit the function of a target nucleic acid at a low concentration and suppress off-target effects, a pharmaceutical composition containing the chimeric molecule, a method for cleaving a target nucleic acid using the chimeric molecule, and a kit for cleaving or diagnosing a target nucleic acid that contains the chimeric molecule. [Brief description of the drawings]

[0010] [Figure 1]This figure shows polyacrylamide gel electrophoresis of the cleavage products of the PRPD-RNA complex by RNaseH, using a system in which each was mixed with 10 times the amount of RNA whose 5' end was labeled with a fluorescent dye. Lane 1 shows the ladder and base sequence of RNA1, lane 2 shows the polyacrylamide gel electrophoresis pattern of the RNA1 cleavage products by RNaseH when 60 U / μL of RNaseH was added to the complex of DNA1 and RNA1, lane 3 shows the polyacrylamide gel electrophoresis pattern of the RNA1 cleavage products when 60 U / μL of RNaseH was added to the complex of DNA1 and RNA1, lane 4 shows the polyacrylamide gel electrophoresis pattern of the RNA1 cleavage products when 60 U / μL of RNaseH was added to the complex of PRPD1 and RNA1, and lane 5 shows the polyacrylamide gel electrophoresis pattern of the RNA1 cleavage products when 6 U / μL of RNaseH was added to the complex of PRPD1 and RNA1. [Figure 2A] FIG. 1 shows the cleavage site of RNA1 by RNaseH in the case of the DNA1-RNA1 complex. [Figure 2B] FIG. 1 shows the cleavage site of RNA1 by RNaseH in the PRPD1-RNA1 complex. [Diagram 3] This is a diagram showing the analysis of RNaseH-cleaved products of the complexes of DNA1, PRPD4, PRPD1 or PD2 with RNA1 by polyacrylamide gel electrophoresis using a system in which 10 times the amount of each was mixed with RNA whose 5' end was labeled with a fluorescent dye. Lane 1 shows the polyacrylamide gel electrophoresis patterns of the products of RNA1 cleaved by RNaseH when RNA1 (control), DNA1, PRPD4, PRPD1, or PD2 was added, respectively. Lane 6 shows the ladder and base sequence of RNA1. [Figure 4] This is a diagram showing the analysis by polyacrylamide gel electrophoresis of the cleavage products of the complex of RNA2, PRPD7, or PD1 with RNA2 by RNase H using a system mixed with 10 times the amount of RNA whose 5' end was labeled with a fluorescent dye. Lane 1 shows the ladder and base sequence of RNA2, and lanes 2 to 5 show the polyacrylamide gel electrophoresis patterns of the RNA2 cleavage products by RNase H when RNA2 (control), DNA2, PRPD7, or PD1 were added, respectively. [Diagram 5]This is a diagram showing the analysis of RNaseH-induced cleavage products of the complex of DPRP1 or PRPD5 and RNA1 by polyacrylamide gel electrophoresis using a system in which 10 times the amount of each was mixed with RNA whose 5' end was labeled with a fluorescent dye. Lane 1 shows the ladder and base sequence of RNA1, and lanes 2 to 8 show the polyacrylamide gel electrophoresis patterns of the RNA1 cleavage products by RNaseH when RNA1 (control), PRPD5 (10 nM), PRPD5 (1 nM), PRPD5 (0.1 nM), DPRP1 (10 nM), DPRP1 (1 nM), and DPRP1 (0.1 nM) were added, respectively. [Figure 6] FIG. 1 shows the RNA cleavage sites of the DPRP1-RNA1 complex by RNaseH. [Figure 7] This shows the antisense activity of PRPD2 and DNA2 in a cell-free translation system. Lanes 1 to 3 show the results in the absence of RNase H, and lanes 4 to 6 show the results in the presence of RNase H. Lanes 1 and 4 show the control, lanes 2 and 5 show the case where DNA2 was added, and lanes 3 and 6 show the case where PRPD2 was added. [Figure 8] Antisense activity of PRPD5 and DPRP2 in a cell-free translation system. Lanes 1, 3, and 5 show the results in the absence of RNase H, and lanes 2, 4, and 6 show the results in the presence of RNase H. Lanes 1 and 2 show the control, lanes 3 and 4 show the case where PRPD5 was added, and lanes 5 and 6 show the case where DPRP2 was added. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] [Chimeric molecule] The chimeric molecule of the present invention comprises a first nucleic acid or a derivative thereof capable of binding to a target nucleic acid fused to a second nucleic acid or a derivative thereof capable of binding to the target nucleic acid and having an anionic main chain backbone.

[0012] In the present invention, the derivative of nucleic acid is not particularly limited, but examples thereof include halogenated derivatives of uracil, cytosine, thymine, adenine, guanine, or a purine ring or pyrimidine ring in which the base moiety bound to the nucleic acid is uracil, cytosine, thymine, adenine, guanine, or a purine ring or pyrimidine ring, or derivatives having a sulfur atom instead of the oxygen atom of each nucleic acid base.

[0013] The first nucleic acid or its derivative having the ability to bind to the target nucleic acid preferably has a neutral or cationic backbone, more preferably neutral. The neutral backbone is not particularly limited, and may be, for example, an amide backbone. The nucleic acid or its derivative having the amide backbone may be, for example, a peptide nucleic acid or its derivative (hereinafter, sometimes referred to as PNA), a peptide ribonucleic acid or its derivative (hereinafter, sometimes referred to as PRNA), or a combination of PRNA and PNA (hereinafter, also referred to as PNA / PRNA). In PNA / PRNA, the binding position of PRNA in PNA may be any position of PNA, or may be bound in the middle of PNA. For example, a combination such as PNA-PRNA-PNA may be used.

[0014] The cationic main chain skeleton is not particularly limited, and examples thereof include an imino skeleton, a phosphoric acid amide skeleton, a phosphoramidite skeleton, etc. Examples of the nucleic acid or a derivative thereof having each of the skeletons include morpholino type nucleic acid, etc.

[0015] The main chain backbone of the second nucleic acid or its derivative, which has the ability to bind to the target nucleic acid and has an anionic main chain backbone, is not particularly limited, but is preferably a sugar-phosphate backbone. Examples of the nucleic acid or its derivative having a sugar-phosphate backbone include ribonucleic acid (hereinafter also referred to as RNA), deoxyribonucleic acid (hereinafter also referred to as DNA), etc.

[0016] The target nucleic acid is not particularly limited as long as it is a nucleic acid or a derivative thereof having a target sequence to which the chimeric molecule of the present invention can bind, but RNA or DNA is preferred. When the chimeric molecule of the present invention is used as a pharmaceutical composition, the target nucleic acid is preferably RNA or DNA encoding a protein that causes a disease to be treated using the pharmaceutical composition.

[0017] The first nucleic acid or a derivative thereof may be fused to either the 3' end or the 5' end of the second nucleic acid or a derivative thereof.

[0018] Examples of the chimeric molecule of the present invention in which the first nucleic acid or a derivative thereof is fused with the second nucleic acid or a derivative thereof include a fusion of the first nucleic acid or a derivative thereof, PNA, with the second nucleic acid or a derivative thereof, DNA (hereinafter, also referred to as a PNA-DNA chimeric molecule), and a fusion of the first nucleic acid or a derivative thereof, PNA / PRNA, with the second nucleic acid or a derivative thereof, DNA, and the like. Examples of the fusion of the first nucleic acid or a derivative thereof, PNA / PRNA, with the second nucleic acid or a derivative thereof, DNA, include a chimeric molecule in which PNA / PRNA is fused to the 5' side of DNA (hereinafter, referred to as a PNA / PRNA-DNA chimeric molecule, P R PD), and a chimeric molecule in which PNA / pRNA is fused to the 3' end of DNA (hereafter referred to as DNA-PNA / pRNA chimeric molecule, DP R P) and the like.

[0019] The chimeric molecule of the present invention can be produced as follows. A PNA-DNA chimeric molecule in which the first nucleic acid is PNA and the target second nucleic acid is DNA can be produced, for example, as follows.

[0020] (Synthesis of PNA Oligomers) PNA oligomers can be synthesized by known solid phase peptide synthesis methods, for example, by using a benzoyl-protected Fmoc PNA monomer and Fmoc-solid phase peptide synthesis (hereinafter also referred to as Fmoc-SPPS method) according to the steps shown below.

[0021] [ka]

[0022] In the above, the lysine residue at the N-terminus or C-terminus is introduced to improve water solubility and suppress acyl transfer reaction. The synthesis can be performed by a known method using NovaSyn (registered trademark) TGR resin or the like. The condensation reaction of the benzoyl group-protected Fmoc-PNA monomer can be performed, for example, by treating with an NMP (N-methylpyrrolidone) solution containing Fmoc-PNA(Bz)-OH (10 equivalents), HATU (1-[bis(dimethylamino)methyliumyl]-1H-1,2,3-triazolo[4,5-b]pyridine-3-oxide hexafluorophosphate; 10 equivalents), HOAt (1-hydroxy-7-azabenzotriazole; 10 equivalents) and DIEA (N,N-diisopropylethylamine; 20 equivalents) for 30 minutes. The Fmoc group can be removed by treating with an NMP solution containing 20% ​​piperidine for 20 minutes. These coupling and Fmoc group removal steps are repeated until the desired sequence is reached. The benzoyl group can be deprotected by treatment with 28% aqueous ammonia at 60°C. Finally, the Boc group of the lysine residue is dissociated and deprotected by treatment with a mixture of TFA (trifluoroacetic acid) / TIPS (triisopropylsilane) / phenol / water (94:3:1:2). The resulting crude product can be purified by reversed-phase HPLC, and the purified product can be identified by ESI-TOF-MS.

[0023] (Synthesis of PNA-DNA chimeric molecules) A PNA-DNA chimeric molecule can be synthesized, for example, as follows, by applying a benzoyl-protected Fmoc monomer, synthesized by a known method, to a target sequence.

[0024] [ka]

[0025] The N-terminus of the PNA molecule is modified with glycine to suppress acyl transfer reaction. The synthesis starts with the construction of a DNA molecule by an automated DNA / RNA synthesizer using CPG resin bound to an adenine residue for DNA synthesis.

[0026] The DNA molecule can be extended by the conventional phosphoramidate method using 5-BMT as an activator. The 5'-amino modified deoxynucleotide derivative is introduced to the 5' end of the DNA molecule using 5'-MMTr (monomethoxytrityl) amino deoxynucleotide phosphoramidate prepared by a known method. After the introduction of the 5' amino modified derivative by a DNA synthesizer, the MMTr group at the 5' end of the DNA is removed by treating with 3% TCA / DCM solution for 15 minutes. Next, the 5' amino group of the DNA is used to extend the DNA by the Fmoc-SPPS method in order to bind PNA via an amide bond.

[0027] The condensation reaction using benzoyl-protected FmocPNA is carried out for 30 minutes in an NMP solution containing Fmoc-PNA(Bz)-OH (10 equivalents), HATU (10 equivalents), HOAt (10 equivalents), and DIEA (20 equivalents). Acetyl capping of unreacted amino groups on the resin can be carried out with 25% acetic anhydride / DCM. The Fmoc group can be removed by treatment with 20% piperidine / NMP. These coupling, acetyl capping, and Fmoc removal steps are repeated until the desired sequence is obtained. Finally, the benzoyl group and the cyanoethyl group of the DNA molecule are dissociated and deprotected by treatment with 28% ammonia for 60 minutes. The resulting crude product can be purified by reversed-phase HPLC, and the purified product can be identified by MALDI-TOF-MS.

[0028] (PNA / PRNA-DNA chimeric molecule; P R Synthesis of PD) PNA / PRNA fused to the 5' end of DNA R The synthesis of PD can be carried out in the same manner as in the synthesis of the PNA-DNA chimeric molecule, for example, by the steps shown below.

[0029] [ka]

[0030] The RPNA monomer can be introduced into a specific position of the PNA molecule based on the Fmoc-SPPS method. The PRNA monomer (Fmoc-γPRNA-OH) can be prepared, for example, by the following steps.

[0031] [ka]

[0032] The crude product can be purified by reverse phase HPLC and the purified product can be identified by MALDI-TOF-MS.

[0033] (DNA-PNA / PRNA chimeric molecule; DPR Synthesis of P DP, in which PNA / pRNA is fused to the 3' end of DNA R Synthesis of P can be carried out, for example, by the Fmoc-SPPS method using a DNA synthesizer according to the following steps.

[0034] [ka]

[0035] The synthesis begins with the incorporation of Fmoc-Gly-OH onto NovaSyn® TGA resin using the condensation reagents 1-(3-dimethylaminopropyl)-3-ethylalbodiimide hydrochloride (EDC·HCl) and a solution of 4-dimethylaminopyridine in DMF (N,N-dimethylformamide).

[0036] The synthesis is preferably carried out using Fmoc-Gly functional TGA resin for the Fmoc-SPPS method. PNA / PRNA molecules can be synthesized by elongating them by the Fmoc-SPPS method using benzoyl-protected Fmoc-PNA and Fmoc-γPRNA monomers. The coupling conditions can be the same as those for PNA-DNA chimeric molecules. After completion of Fmoc-SPPS, the 2',3'-hydroxy groups of the PRNA molecule are protected with acetyl groups. After removal of the N-terminal Fmoc group, the resin is used in a DNA synthesizer to elongate the DNA molecule from the amino group at the N-terminus of the PNA / PRNA molecule bound by a phosphoamidate bond using the known phosphoamidate method. Finally, dissociation and deprotection are carried out with 28% ammonia. The resulting crude product can be purified by reversed-phase HPLC, and the purified product can be identified by MALDI-TOF-MS.

[0037] (Action against nucleases) The complex consisting of the chimeric molecule of the present invention and the target nucleic acid bound to the chimeric molecule specifically binds to a nuclease. As the nuclease, ribonuclease H is preferably used, but it is not limited thereto, and any nuclease that specifically binds to the complex is not particularly limited with respect to the type of ribonuclease.

[0038] The nuclease has a site that recognizes the second nucleic acid or its derivative (hereinafter also referred to as the nucleic acid recognition site) and a nuclease active site that cleaves the target nucleic acid. The nucleic acid recognition site of the nuclease has a channel structure composed of basic amino acid residues, and therefore binds to the second nucleic acid or its derivative having an anionic backbone. When the second nucleic acid or its derivative binds to the nucleic acid recognition site, the first nucleic acid or its derivative fused to the second nucleic acid or its derivative is attracted to the cleavage active site of the nuclease, and the target nucleic acid can be selectively cleaved at the fusion (junction) site of the first nucleic acid or its derivative and the second nucleic acid or its derivative.

[0039] The chimeric molecule of the present invention can cleave a target sequence bound to the chimeric molecule of the present invention at the fusion (junction) site between the first nucleic acid or a derivative thereof and the second nucleic acid or a derivative thereof. Therefore, by designing a chimeric molecule in which the induction site is used as the cleavage site for the target nucleic acid, the target nucleic acid can be cleaved at a desired location.

[0040] In the chimeric molecule of the present invention, the melting temperature (Tm) of both target nucleic acid fragments after cleavage with the nuclease is preferably below body temperature, for example, 38°C or below, and may be 37°C or below, 30°C or below, or 25°C or below. By making the Tm of both target nucleic acid fragments below body temperature, both target nucleic acid fragments generated by cleavage at one site with the nuclease can be quickly dissociated from the nuclease. On the other hand, after cleavage of the target nucleic acid with the nuclease, the chimeric molecule of the present invention is quickly dissociated from the nuclease, so that the chimeric molecule of the present invention is quickly used for cleavage of the next target nucleic acid, enabling highly efficient turnover of cleavage of the target nucleic acid by the nuclease. Therefore, the chimeric molecule of the present invention can cleave the target nucleic acid at a low concentration, thereby reducing off-target effects.

[0041] [Pharmaceutical composition] The pharmaceutical composition of the present invention contains the chimeric molecule of the present invention as an active ingredient.

[0042] In the present invention, the pharmaceutical composition is not particularly limited, and examples thereof include pharmaceutical compositions for treating diseases caused by a protein encoded by a target nucleic acid targeted by the chimeric molecule of the present invention, such as antitumor agents, agents for treating ischemic brain diseases, etc. The pharmaceutical composition of the present invention can cleave a target nucleic acid with an endogenous nuclease and inhibit the expression of a protein encoded by the target nucleic acid, and therefore can treat a disease caused by a protein encoded by the target nucleic acid. The protein encoded by the target nucleic acid may in principle be any protein that is a target of the pharmaceutical composition of the present invention. For example, TGFβ, which is a therapeutic target for idiopathic pulmonary fibrosis, p53, which is a therapeutic target for cancer, and the oncogene ras, VEGF165, which is a therapeutic target for age-related macular degeneration, etc., are examples of proteins that can be targeted by the pharmaceutical composition of the present invention. The disease is not particularly limited, and examples thereof include cancer, ischemic brain disease, age-related macular degeneration, familial hypercholesterolemia, muscular dystrophy, dementia, NASH, liver cirrhosis, idiopathic pulmonary fibrosis, liver disease, autoimmune disease, kidney disease, hematopoietic disease, atopic skin disease, and psoriasis.

[0043] The pharmaceutical composition of the present invention can be in various forms, such as a liquid (e.g., an injection), a dispersion, a suspension, a tablet, a pill, a powder, a suppository, etc. A preferred embodiment is an injection, which is preferably administered parenterally (e.g., intravenously, transdermally, intraperitoneally, intramuscularly).

[0044] The pharmaceutical composition of the present invention may be used not only as a single agent according to the above dosage form, but also as a combination agent with a nucleic acid drug of a different composition, or a low molecular weight drug or an antibody drug, etc., and the dosage form and delivery system used for administration may be selected from the most suitable ones. In addition, various administration methods may be selected, such as encapsulation in a micelle or binding to an antibody drug, etc., by using the pharmaceutical composition of the present invention as is or by modifying it. The pharmaceutical composition of the present invention may vary depending on the type of disease, the type of target nucleic acid, etc., and may be, for example, 0.025 to 50 mg / kg, preferably 0.1 to 50 mg / kg, more preferably 0.1 to 25 mg / kg, and even more preferably 0.1 to 10 mg / kg or 0.1 to 3 mg / kg, but is not limited thereto.

[0045] [Method for cleaving target nucleic acid and kit for cleaving target nucleic acid or for diagnosis] The method for cleaving a target nucleic acid of the present invention uses the chimeric molecule of the present invention and a nuclease. Examples of the nuclease include those mentioned above. The method for cleaving a target nucleic acid of the present invention can specifically cleave a target sequence, so that the method can be used for sequence-selective cleavage of a target nucleic acid, a genome editing tool, and the diagnosis of a disease caused by a protein encoded by the target nucleic acid.

[0046] The target nucleic acid cleavage or diagnostic kit of the present invention includes the chimeric molecule of the present invention and a nuclease. Examples of the nuclease include those described above. The target nucleic acid cleavage kit of the present invention can include, in addition to the chimeric molecule of the present invention and the nuclease, other components necessary for detecting a target nucleic acid fragment, such as an acrylamide gel, a reaction buffer, a reaction vessel, etc. The target nucleic acid cleavage kit of the present invention can specifically cleave a target nucleic acid, and can therefore be used as a sequence-selective target nucleic acid cleavage or genome editing tool. The diagnostic kit of the present invention can also be used to diagnose a disease caused by a protein encoded by a target nucleic acid targeted by the chimeric molecule of the present invention. Examples of the protein encoded by a target nucleic acid targeted by the chimeric molecule of the present invention include those described above. The diagnostic kit of the present invention can determine whether a target nucleic acid is contained in a biological sample from a subject by detecting whether a nucleic acid in the biological sample from a subject can be cleaved by the diagnostic kit of the present invention, and can therefore diagnose whether the subject suffers from a disease caused by a protein encoded by a target nucleic acid targeted by the chimeric molecule of the present invention. The biological sample is not particularly limited, and examples thereof include blood, saliva, urine, cerebrospinal fluid, bone marrow fluid, pleural effusion, ascites, synovial fluid, tears, aqueous humor, vitreous humor, lymphatic fluid, and the like. Furthermore, by introducing the components of the diagnostic kit of the present invention into the body, it is possible to detect outside the body structural changes and physicochemical changes in the detection probe molecule caused by the internal environment or the presence or absence and concentration of the target molecule, or to measure with high sensitivity outside the body the energy changes caused by light, magnetism, ultrasound, radiation, etc. irradiated or exposed from outside the body, or to visualize them as images, for application in in vitro diagnosis. EXAMPLES

[0047] The present invention will now be described in more detail with reference to examples, but the present invention is not limited to the following examples.

[0048] [Example 1] Preparation of PNA-DNA chimeric molecule PNA-DNA chimeric molecules were synthesized by automated DNA synthesis and the Fmoc-SPPS method using CPG resin. The synthesis started with the construction of DNA molecules by an automatic DNA synthesizer. CPG resin (1 μM scale) bearing 2'-deoxyadenosine residues bound to adenine residues for DNA synthesis was introduced into the DNA synthesizer, and the DNA molecules were extended by the conventional phosphoramidate method using 5-BMT as an activator. The concentration of the phosphoramidate solution was 70-78 mM in acetonitrile. 5'-amino modified deoxycytidine derivatives were introduced into the 5'-end of the DNA molecules using 5'-MMTrNH deoxycytidine phosphoramidate prepared by a known method. After the introduction of the 5'-amino modified derivatives by the DNA synthesizer using the final trityl "ON" step, the resin was removed from the DNA synthesizer and transferred to a reaction column for the Fmoc-SPPS step. The MMTr group at the 5'-end of DNA was removed by treatment with 3% TCA / DCM solution for 15 min.

[0049] Next, PNA was extended by the Fmoc-SPPS method using the 5' amino group of DNA as the basis for the amide bond. The resin was treated with 20% piperidine / NMP to make the surface amino groups basic, filtered, and washed with NMP at least five times. Condensation reaction with benzoyl-protected FmocPNA monomer was carried out by treatment with NMP solution (300 μL) containing Fmoc-PNA(Bz)-OH (10 equiv.), HATU (10 equiv.), HOAt (10 equiv.), and DIEA (20 equiv.). After reaction at room temperature for 30 min with occasional strong stirring, the solution was removed and the resin was washed with NMP at least three times.

[0050] Next, the resin was added with 20% piperidine in NMP and stirred occasionally for 20 minutes to remove the Fmoc group. After the Fmoc group removal was completed, the resin was washed with NMP for more than five times. The condensation reaction and Fmoc removal steps were repeated until the desired sequence of the PNA-DNA chimeric molecule was constructed. Finally, to suppress molecular acyl transfer within the N-terminal amino group of the PNA residue, Fmoc-Gly-OH was introduced under the same condensation conditions as above. After the Fmoc-SPPS step was completed, the resin was treated with 28% ammonia solution at 60°C for 16 hours to remove all protecting groups and was separated from the resin. The resin was then removed by filtration, and the filtrate was concentrated. The crude product was purified by HPLC using COSMOSIL 5C. 18 The product was purified by reverse-phase HPLC using an AR-II column (Nacalai Tesque, 10Φ×250 mm) at a flow rate of 3 mL / min with a linear gradient of 5% to 70% for 30 min using solvent A: 0.1 M TEAA buffer (pH 7.5), solvent B: 0.1 M TEAA (pH 7.5) / acetonitrile (1:1, v / v). By the above method, two types of PNA-DNA chimeric molecules (PD1 and PD2) shown in Table 1 below were produced.

[0051] [Table 1]

[0052] [Example 2] P R PD production P is a DNA-PNA / PRNA chimera in which PNA / PRNA is fused to the 5' end of DNA. R PD was synthesized by a combination of an automated DNA synthesizer and the Fmoc process using CPG resin. The synthesis started with the construction of DNA molecules by automated DNA synthesis. CPG resin (1 μM scale) carrying 2' deoxynucleoside residues was introduced into the DNA synthesizer, and the DNA molecules were extended by the conventional phosphoramidate method using 5-BMT as an activator. The concentration of the phosphoramidate solution was 70-78 mM in acetonitrile. The 5' amino-modified deoxynucleoside derivatives were introduced into the 5' end of the DNA molecules using 5'-MMTrNH deoxycytidine phosphoramidate prepared by a known method.

[0053] After the introduction of the 5' amino modified derivatives by the DNA synthesizer using the final trityl "ON" step, the resin was removed from the DNA synthesizer and transferred to a reaction column for the Fmoc-SPPS step. The MMTr group at the 5' end of the DNA was removed by treatment with 3% TCA / DCM solution for 15 min.

[0054] The PNA was then extended by the Fmoc-SPPS method using the 5' amino group of DNA as the basis for the amide bond. The resin was treated with 20% piperidine / NMP to basify the surface amino groups, filtered, and washed with NMP five times or more. Condensation reactions using benzoyl-protected FmocPNA monomers were carried out using an NMP solution (300 μL) containing Fmoc-PNA(Bz)-OH (10 equivalents), HATU (10 equivalents), HOAt (10 equivalents), and DIEA (20 equivalents). After reaction at room temperature for 30 minutes with occasional strong stirring, the solution was removed and the resin was washed with NMP at least three times.

[0055] Next, 20% piperidine solution in NMP was added to the resin and stirred occasionally for 20 min to remove the Fmoc group. After the completion of Fmoc group removal, the resin was washed with NMP for more than five times. The condensation reaction and Fmoc removal process were repeated until the desired PNA-DNA chimera sequence was constructed. Finally, to suppress molecular acyl transfer within the N-terminal amino group of the PNA residue, Fmoc-Gly-OH or Fmoc-Lys(Fmoc)-OH was introduced under the same condensation conditions as above. After the Fmoc-SPPS step was completed, the resin was treated with 28% ammonia solution at 60° C. for 16 hours to remove all protecting groups and to separate it from the resin. The resin was then removed by filtration and the filtrate was concentrated. 18 The product was purified by reverse-phase HPLC using an AR-II column (Nacalai Tesque, 10Φ×250 mm) at a flow rate of 3 mL / min with a linear gradient of 5% to 70% for 30 min using solvent A: 0.1 M TEAA buffer (pH 7.5), solvent B: 0.1 M TEAA (pH 7.5) / acetonitrile (1:1, v / v). By the above method, the seven types of P shown in Table 2 R PD(P R PD1~P R PD7) was manufactured.

[0056] [Table 2]

[0057] [Example 3] DP R Production of P Fmoc-Gly-OH (30 mg, 100 μmol) and EDC·HCl (19 mg, 100 μmol) were dissolved in DMF (1.0 mL) and the solution was stirred for 35 min under ice cooling. The ice cooling was removed and NovaSyn® TGA resin (42 mg, 10 μmol of hydroxy groups) in DMF and DMAP (1.2 mg, 10 μmol) was added to the solution and the resulting mixture was stirred at room temperature for 1.5 h. The resin was filtered and washed successively with NMP, DCM / ethanol (1:1, v / v) and DCM.

[0058] After thoroughly washing the resin, 1.0 mL of benzoic anhydride (113 mg, 0.5 mmol) in 20% pyridine / NMP was added to the resin, and the mixture was left at room temperature with occasional shaking. After standing for 1 h, the resin was thoroughly washed with NMP and DCM. After washing with ethanol, the resin was dried in a desiccator under reduced pressure to obtain Fmoc-Gly functionalized TGA resin (41 mg, 94%). The amount of Fmoc-Gly-OH introduced was calculated by quantitative UV (301 nm) measurement of Fmoc-piperidine liberated by 20% piperidine / NMP treatment.

[0059] The Fmoc-Gly functionalized TGA resin (1 μmol scale) obtained above was washed with NMP and treated with 20% piperidine / NMP at room temperature for 20 minutes to remove the Fmoc protecting group. After thorough washing with NMP, the resin was added to an NMP solution (300 μL) of Fmoc-PNA(Bz)-OH or Fmoc-γRPNA-OH (10 equivalents), HOAt (10 equivalents), HATU (10 equivalents) and DIEA (20 equivalents), and the mixture was left at room temperature for 30 minutes with occasional shaking. This coupling step was repeated twice. After washing with NMP and DCM, the resin was treated with 25% acetic anhydride / DCM at room temperature for 10 minutes. After the above coupling step, the resin was washed with DCM and NMP. Subsequently, Fmoc was removed by treatment with 20% piperidine / NMP at room temperature for 20 minutes. The same Fmoc removal, coupling, and capping steps were used for the elongation of the PNA-PRNA chain. After the last coupling step, the resin was washed thoroughly with NMP and DCM, and then with pyridine. Then, acetic anhydride / DCM (2:3, v / v) was added to the resin and left at room temperature for 2 h with occasional shaking to protect the 2' and 3' hydroxyl groups of the PRNA molecule.

[0060] After removal of the N-terminal Fmoc protecting group, the resin was transferred to an empty column for an automated DNA / RNA synthesizer, and the column containing the resin was placed in the DNA / RNA synthesizer. The DNA strand was extended by the standard phosphoramidate method using the 5'-O-DMTr-3'-O-(2-cyanoethyl) phosphoramidate building block. After strand assembly, the resin was treated with 28% aqueous ammonia at 60°C for 18 h to elongate the DP R P was deprotected and released. The resin was then removed by filtration through a membrane filter. The filtrate was partially concentrated in vacuum and diluted with 5C. 18 -Purified using reversed-phase HPLC on an AR-II column (10 × 250 nm) and DP R I got P. Using the above method, two types of DPs shown in Table 3 were R P(DP R P1, D.P. R P2) was manufactured.

[0061] [Table 3]

[0062] [Example 4] Measurement of RNase activity P R The RNA cleavage activity of the PD·RNA complex by RNase was examined as follows. The 5'-FAM-labeled RNA (5'-FAM-GAAUCUUAUAGUCUUGCA-3'; RNA1) having the target nucleotide sequence represented by SEQ ID NO: 12 was subjected to PCR using the PCR product obtained in Example 2. R The mixture was annealed and mixed with 0.1 equivalent of PD1. R The PD·RNA complex was allowed to form. Next, 60 U / μL of RNase H was added to the mixture and reacted at 37°C to cleave RNA1. After reacting for 30 minutes, the reaction was stopped by adding 7M uric acid Tris-HCl buffer, and then RNase H was inactivated at 70°C for 10 minutes. R As a control for PD1, the same treatment was performed on the counterpart DNA1 (5'-TGCAAGACTATAAGATTC-3') having the base sequence shown in SEQ ID NO: 13. The cleaved RNA fragments were analyzed by 20% resolution polyacrylamide gel electrophoresis (resolution PAGE), visualization and quantification using a fluorescent image analyzer. The results are shown in Figure 1 and Table 4.

[0063] [Table 4]

[0064] As shown in Figure 1 and Table 4, in the case of DNA1 treated with 60 U / μL of RNase H, 54% of RNA1 was cleaved. R In the case of PD1, more than 99% of RNA1 was cleaved, which indicates saturation of the activity of RNase H. Therefore, we performed the same RNA cleavage experiment by reducing the amount of RNase H to 6 U / μL. As a result, as shown in Figure 1 and Table 4, in the case of DNA1, the degree of cleavage of RNA1 was reduced to 12%, whereas in the case of P RIn the case of PD1, RNA1 cleavage was maintained at more than 90%. This result indicates that RNaseH is more efficient at cleaving P compared to the DNA1·RNA1 complex. R It was found that the PD1·RNA1 complex exhibited eight-fold higher RNA1 cleavage activity.

[0065] P R In the case of PD1, the cleavage site was a single site near the PNA-DNA amide bond, as shown in Figure 2B. In contrast, in the case of DNA1, cleavage occurred at multiple sites, as shown in Figure 2A. The minimum DNA length for RNaseH to bind is 5 to 6 bases, which corresponds to the distance between the DNA binding channels of RNaseH. Therefore, P R The DNA molecule of PD1 consists of seven DNA nucleobases, which are precisely recognized by the DNA binding channel of RNaseH to introduce a single cleavage site. DNA·RNA heterocomplexes using 5-6 base pairs can be bound at several sites, which induces multiple-site RNA cleavage. Based on these, the promotion of the above RNA cleavage is explained as follows.

[0066] Since RNaseH does not have base sequence selectivity for target RNA, in the case of DNA1, the cleavage sites of the complex with the target RNA are varied, and it is highly likely that a single cleavage will not induce dissociation of the complex. Therefore, the cleaved RNA cannot dissociate from the ASO-cleaved RNA-RNaseH complex, and the turnover frequency of DNA1 is low. R In the case of PD1, cleavage can be achieved at one site of the target RNA, particularly at a sequence where the stability of the cleaved complex is below body temperature (37°C), and the complex dissociates efficiently after one cleavage, allowing it to bind to other uncleaved target RNA, which is thought to enable a dramatic increase in turnover rate. This was demonstrated by calculating the Tm of the complex between the ASO and both fragments of the cleaved RNA1·DNA1 complex after cleavage using actual measurements and the nearest neighbor method using thermodynamic parameters.

[0067] As shown in Figure 2A, in the case of DNA1, cleavage was observed nonspecifically at various sites (a to e). Calculating the stability of the complex after cleavage, the complex after cleavage with DNA1 had Tm = 35.3 °C and 37.2 °C for cleavage at site a and site d, respectively. This is almost the same as body temperature (37 °C), and it is expected that the complex is difficult to dissociate even after cleavage. Even with cleavage at other sites, the Tm of the complex with the cleaved fragment was often 37 °C or higher. For some cleavage fragments (sites b and c), the Tm of the complex between the RNA fragment and DNA1 after cleavage was 37 °C or lower, but the probability of its generation was not high. For this reason, multiple RNaseH cleavage is generally required to dissociate the complex, suppressing the turnover number of RNaseH cleavage.

[0068] In contrast, P R PD1 exhibits selective single RNA cleavage at PNA-DNA junctions, which is consistent with the RNA1·P R This greatly reduces the temperature stability of the PD1 complex. Thus, after one RNaseH cleavage, the complex dissociates and the ASO is able to immediately form a complex with the uncleaved target RNA, thereby enhancing the RNaseH cleavage turnover rate and cleaving all of the RNA1 in this experiment. R The Tm of the PD1 complex was calculated.

[0069] As shown in Figure 2B, the major cleavage site was one of the sites a. Thus, the resulting fragments were R PD1 complexed with a DNA molecule (cleaved RNA DNA complex), P R P such as PD1 complexed with a PNA / PRNA molecule (cleaved RNA·PNA / PRNA complex). RThe cleaved RNA·DNA complex forms a different type of complex from that with PD1. The thermal stability of the cleaved RNA·DNA complex was calculated by nearest neighbor thermodynamics parameters, and was found to be Tm = 13.2°C. The thermal stability of the cleaved RNA·PNA / pRNA complex was found to be Tm = 22.3°C by UV temperature melting analysis. PNA has been reported to form unstable complexes with DNA / RNA under physiological high salt conditions. Therefore, this low thermal stability of the cleaved RNA·PNA / pRNA complex is considered reasonable. From the above, selective cleavage of RNA1 at a single site in the PNA-DNA fusion region generates an RNA fragment that is stable at temperatures below body temperature (37°C), and R This is recognized as efficient turnover of PD1.

[0070] Next, we examined the effect of introducing pRNA into the chimera on RNase H activity. R PD4, P R The reaction was carried out in the presence of PD1 or PD2 (10 nM) at 37° C. for 30 minutes. The results are shown in FIG.

[0071] [Table 5]

[0072] In the case of DNA1, the amount of RNA1 cleavage was very small. R PD4 and P R In the presence of 10 nM PD1, over 90% of RNA1 was cleaved. R PD4 and P R The same level of RNase H activity was shown compared to PD1.

[0073] The effect of introducing a chimeric pRNA on RNase H activity was examined using 16mer RNA using RNA2 (5'-FAM-UAAGAAGGAGAUAUAC-3') having the base sequence shown in SEQ ID NO: 14. RNA2 (1 μM) and RNase H (6 × 10 -3 DNA2 (5'-GTATATCTCCTTCTTA-3') having the base sequence shown in SEQ ID NO: 15, R The reaction was carried out in the presence of PD7 or PD1 (10 nM) at 37° C. for 30 minutes. The results are shown in FIG.

[0074] [Table 6]

[0075] In the case of DNA2, 52% of RNA2 was cleaved. R In the presence of PD7, 76% of RNA2 was cleaved, which was 1.5-fold higher than that of DNA2 due to RNase H activity. In contrast, in the presence of PD1, the amount of RNA2 cleaved was 40%, which is consistent with the presence of PD7. R The activity of RNase H was 1.9-fold lower than that of PD7. As a result, the introduction of pRNA into the chimeric molecule was able to enhance RNase H activity, which is considered to be due to the selective binding to RNA in which an A-type complex is formed with the target RNA.

[0076] Next, D.P. R The cleavage activity of target RNA1 by RNaseH of P1 was examined. R The activity was compared with that of PD5. R P is expected to induce RNA cleavage at the 3' end. R P1 or P R The mixture was mixed with 1 / 100, 1 / 1000, or 1 / 10,000 equivalents of PD5, and allowed to anneal to form complexes. -3 U / μL of RNase H was added and reacted for 30 minutes at 37° C. The results are shown in FIG.

[0077] [Table 7]

[0078] As shown in Figure 5, R P1 cleaved RNA at 3-4 base positions from the 3' end of the RNA. The main cleavage sites are shown in Figure 6. The cleavage activity was R At 10 nM of P1, the figure was 43%, which is R This was 1.7 times lower than that of P5 (73%). R This low cleavage activity of P1 is believed to be due to the restricted cleavage site of RNA1. R In the case of PD5, the cleavage site is at one of the PNA-DNA junctions, thus ensuring efficient release of RNA1 and the subsequent cleavage of P R Efficient turnover of PD5 was achieved by generating RNA1 with low temperature stability below 37°C.

[0079] In contrast, D.P. R In the case of P1, cleavage occurs near the 3' end of RNA1, resulting in a long RNA fragment that maintains high temperature stability above 37°C. R The turnover efficiency of P1 is R Decreased compared to PD5.

[0080] [Example 5] Kinetic parameters of RNA cleavage reaction by RNase H P R To investigate the highly efficient RNA cleavage of PD5, we performed a kinetic analysis of RNA cleavage by RNase H. RNase H (1.5 × 10 -3 U / μL = 4.1 nM) in excess of P R The reaction was carried out under pseudo-first-order reaction conditions in the presence of PD1·RNA1 (1, 2, 5, 10 μM). R The time profile of the amount of cleaved RNA1 was plotted against the concentration of PD1·RNA1. Lineweaver-Burk plots were performed using the initial velocities obtained for each substrate concentration.R The same experiment was performed for P1·RNA1. The kinetic parameters obtained from the Lineweaver-Burk plot are summarized in Table 8. The parameters for the DNA·RNA complex were extracted based on the results reported by Otsuka et al. The results are shown in Table 8.

[0081] [Table 8]

[0082] As shown in Table 8, P R RNA cleavage reaction by the PD1·RNA1 complex and RNaseH cat The value was about 1.9 times higher than that of the DNA·RNA complex. This result indicates that RNase H has a higher P value than the corresponding DNA·RNA complex. R The PD1·RNA1 complex showed a slightly improved cleavage efficiency, but the improvement rate was clearly lower than that of the target RNA cleavage experiment shown in Figure 3. RNase H is P R The PD1·RNA1 complex exhibits high cleavage activity and is involved in the P R The Michaelis-Menten constant (Km) for binding to the PD1·RNA1 complex was larger than that for the DNA·RNA complex. R This suggests that the binding activity of PD1·RNA1 complex with RNaseH is lower than that of DNA·RNA complex. cat According to this relationship between P and Km value, the recognition of RNase H is R It is thought that this has little effect on the high RNA cleavage activity of PD1. R The Vmax value of the PD1·RNA1 complex is 4-fold higher than that of the DNA·RNA complex, but this value is smaller than that estimated from gel electrophoresis (e.g., Figure 1). Approximately 8-fold higher RNA cleavage activity is observed (compare lanes 2 and 4). These results suggest that the substrate (P R Binding of RNase H to the PD1-RNA1 complex is not the rate-limiting step, but rather the cleaved P R The dissociation step of the PD1-RNA1 complex from RNaseH is thought to be important for efficient RNA cleavage activity of RNaseH.

[0083] DP R In the case of P1, the k cat The value was smaller than that of the DNA·RNA complex. R P1 exhibits a lower cleavage activity compared to the corresponding DNA. The Vmax value for RNA cleavage was 1.7-fold higher than that of the DNA·RNA complex, while the Km value was 5.2-fold higher than that of the DNA·RNA complex. The higher Km value compared to the DNA-RNA complex is thought to be due to the substitution of the natural DNA backbone with the PNA-PRNA backbone, which induces a decrease in the recognition ability of RNase H. However, DP R The Km value of the P1·RNA1 complex is R This is lower than that of PD1-RNA1, which is R The recognition of RNase H by the P1·RNA1 complex is R DP R P1 RNA1 and P R The difference in Km value between PD1 and RNA1 indicates that DP1 is catalyzed by RNase H. R The recognition site of the P1·RNA1 complex is P R This supports the view that this is different from the recognition site of the PD1-RNA1 complex.

[0084] The cleavage reactions shown in Figure 5 also support the idea that the recognition sites are different. R PD and DP R The different RNase H activity between P and P depends not only on the RNA cleavage site but also on the recognition ability and catalytic activity of RNase H (k cat / Km) is considered to be dependent on this k cat The / Km value can be determined by the substrate concentration depending on the kinetic analysis of the RNA cleavage reaction of RNase H. As shown in Table 8 above, P R PD and DP R Pk cat The / Km values ​​were almost the same order of magnitude (P RPD·RNA: 1.67×10 6 s -1 M -1 , D.P. R P RNA: 1.97×10 6 s -1 M -1 ) This suggests that the turnover efficiency of the chimeric molecule is mainly controlled by the RNA cleavage site. These results indicate that the cleavage site of RNase H is important for promoting the RNA cleavage activity and turnover efficiency of the chimera.

[0085] [Example 6] Antisense activity in a cell-free translation system To confirm the applicability to endogenous RNA cleavage, we used an in vitro cell-free translation system to R The protein synthesis inhibitory activity (antisense activity) of PD was examined. R PD2 and DNA2 are 16-mers containing 5'-GAAGGA-3', which is the complementary sequence of the Shine-Dalgarno (SD) sequence upstream of the Renilla luciferase gene, for the luciferase reporter assay. R PD2 or DNA2) was added in an amount of 1 / 10 equivalent to the target mRNA. The reaction was carried out in the presence and absence of RNaseH to evaluate the RNA cleavage activity of RNaseH. The results are shown in Figure 7.

[0086] As shown in Figure 7, in the absence of RNaseH, almost no antisense activity was observed for DNA2. The inhibitory activity of DNA2 was slightly observed (12%) when RNaseH was added. R In the case of PD2, 9% of antisense activity was observed in the absence of RNaseH, which was slightly higher than that of DNA1. R The antisense activity of PD2 was significantly enhanced by 91% by the addition of RNaseH. This level was lower than the stoichiometric inhibition level in the absence of RNaseH, suggesting that inhibition occurs only through one-to-one complex formation. The addition of only 1 / 10 equivalent of antisense oligonucleotide enhanced the antisense activity of PD2 by 91%. RIn the case of PD2, more than 10% inhibition of protein expression was observed. R This indicates that PD2 acts in a catalytic manner through its RNase H activity. R These results suggest that PD can efficiently cleave target mRNA and inhibit protein production by utilizing RNase H activity. This result is consistent with gel electrophoresis analysis of RNA fragments. Therefore, it is essential to explore the cleavage site of RNA to design more effective ASOs for antisense activity.

[0087] Next, P in a cell-free translation system R PD5 and DP R The antisense activity of P2 was examined using PURSYSTEM Classic II. The experiment was performed in the absence and presence of RNase H. The results are shown in Figure 8. P R PD5 and DP R P2 was added in an amount of 1 / 10 equivalent to the target mRNA encoding the Renilla luciferase gene. R In the case of PD5, the antisense activity was enhanced by 75% by the addition of RNase H. In contrast, the antisense activity of DP R In the case of P2, the antisense activity was enhanced by 12% by the addition of RNase H. R This was 6-fold lower than PD5. [Industrial Applicability]

[0088] According to the present invention, there are provided a chimeric molecule that can inhibit the function of a target nucleic acid at a low concentration and suppress off-target effects, a pharmaceutical composition containing the chimeric molecule, a method for cleaving a target nucleic acid using the chimeric molecule, and a kit for cleaving or diagnosing a target nucleic acid that contains the chimeric molecule.

Claims

1. A chimeric molecule in which a first nucleic acid or a derivative thereof capable of binding to a target nucleic acid is fused with a second nucleic acid or a derivative thereof capable of binding to the target nucleic acid and has an anionic backbone, the main chain backbone of the first nucleic acid or a derivative thereof is an amide backbone, the first nucleic acid or a derivative thereof is a combination of a peptide ribonucleic acid or a derivative thereof and a peptide nucleic acid or a derivative thereof; The first nucleic acid or a derivative thereof is fused to the 5' end of the second nucleic acid or a derivative thereof; the derivative of the first nucleic acid or the derivative of the second nucleic acid is selected from a halogenated derivative of uracil, cytosine, thymine, adenine or guanine bound to the first nucleic acid or the second nucleic acid, a halogenated derivative of a purine ring or a pyrimidine ring bound to the first nucleic acid or the second nucleic acid, a deamino derivative of the first nucleic acid or the second nucleic acid, and a derivative having a sulfur atom instead of an oxygen atom of a base of the first nucleic acid or the second nucleic acid, a complex consisting of the chimeric molecule and the target nucleic acid bound to the chimeric molecule specifically binds to a nuclease; The nuclease cleaves the target nucleic acid at a fusion site between the first nucleic acid or a derivative thereof and the second nucleic acid or a derivative thereof; The chimeric molecule, wherein the melting temperature Tm of both fragments of the target nucleic acid after cleavage with the nuclease is 38° C. or lower.

2. The chimeric molecule of claim 1 , wherein the main chain backbone of the first nucleic acid or derivative thereof is neutral or cationic.

3. The chimeric molecule according to claim 1 or 2, wherein the backbone of the second nucleic acid or a derivative thereof is a sugar-phosphate backbone.

4. The chimeric molecule according to any one of claims 1 to 3, wherein the nuclease is ribonuclease H.

5. The chimeric molecule according to any one of claims 1 to 4, wherein the second nucleic acid or a derivative thereof is DNA.

6. The chimeric molecule according to any one of claims 1 to 5, wherein the target nucleic acid is RNA or DNA.

7. A pharmaceutical composition comprising the chimeric molecule according to any one of claims 1 to 6 as an active ingredient.

8. The pharmaceutical composition according to claim 7 , wherein the pharmaceutical composition is for treating cancer or ischemic brain disease.

9. A method for cleaving a target nucleic acid, comprising cleaving the target nucleic acid in vitro using the chimeric molecule according to any one of claims 1 to 6 and a nuclease.

10. The method for cleaving a target nucleic acid according to claim 9 , wherein the nuclease is ribonuclease H.

11. A kit for cleaving a target nucleic acid or for diagnosis, comprising the chimeric molecule according to any one of claims 1 to 6 and a nuclease.

12. The kit of claim 11 , wherein the nuclease is RNase H.

Citation Information

Patent Citations

  • Template-dependent ligation using pna-dna chimeric probes

    JP2003511059A

  • Double-stranded nucleic acid binder, said binder—double-stranded nucleic acid complex, pharmaceutical composition containing said complex, and production method for said complex

    WO2014148620A1